Clinical Trial Update: Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 study of Sym004 in adults with recurrent glioblastoma has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Sym004

Snippet

Sponsor: Annick Desjardins | Conditions: Malignant Glioma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-24